Precision BioSciences, Inc.
DTIL
$4.69
$0.204.45%
| Weiss Ratings | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | C- | |||
| Rating Factors | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.10 | |||
| Price History | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -16.84% | |||
| 30-Day Total Return | -16.99% | |||
| 60-Day Total Return | -1.26% | |||
| 90-Day Total Return | -34.50% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -66.97% | |||
| 2-Year Total Return | -79.82% | |||
| 3-Year Total Return | -95.32% | |||
| 5-Year Total Return | -97.18% | |||
| 52-Week High % Change | -71.88% | |||
| 52-Week Low % Change | 24.38% | |||
| Price | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $15.97 | |||
| 52-Week Low Price | $3.61 | |||
| 52-Week Low Price (Date) | Dec 31, 2024 | |||
| 52-Week High Price (Date) | Apr 03, 2024 | |||
| Valuation | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 47.06M | |||
| Enterprise Value | -9.20M | |||
| Price/Earnings (TTM) | 2.37 | |||
| Earnings Per Share (TTM) | 1.89 | |||
| Earnings Per Share Growth | -111.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.52 | |||
| Price/Book (Q) | 0.65 | |||
| Enterprise Value/Revenue (TTM) | -0.13 | |||
| Price | $4.69 | |||
| Enterprise Value/EBITDA (TTM) | 0.40 | |||
| Enterprise Value/EBIT | 0.35 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 8.00M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 919 314 5512 | |||
| Address | 302 East Pettigrew Street Durham, NC 27701 | |||
| Website | www.precisionbiosciences.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -38.08% | |||
| Profit Margin | 10.43% | |||
| Management Effectiveness | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -11.04% | |||
| Return on Equity | 19.05% | |||
| Income Statement | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 68.70M | |||
| Total Revenue (TTM) | 68.70M | |||
| Revenue Per Share | $8.59 | |||
| Gross Profit (TTM) | 68.70M | |||
| EBITDA (TTM) | -22.76M | |||
| EBIT (TTM) | -26.16M | |||
| Net Income (TTM) | 7.17M | |||
| Net Income Avl. to Common (TTM) | 7.17M | |||
| Total Revenue Growth (Q YOY) | -90.93% | |||
| Earnings Growth (Q YOY) | -32.09% | |||
| EPS Diluted (TTM) | 1.89 | |||
| EPS Diluted Growth (Q YOY) | 45.35% | |||
| Balance Sheet | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 86.31M | |||
| Cash Per Share (Q) | $10.79 | |||
| Total Current Assets (Q) | 94.99M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 56.39M | |||
| Current Ratio (Q) | 6.341 | |||
| Book Value Per Share (Q) | $6.87 | |||
| Total Assets (Q) | 136.39M | |||
| Total Current Liabilities (Q) | 14.98M | |||
| Total Debt (Q) | 30.05M | |||
| Total Liabilities (Q) | 80.00M | |||
| Total Common Equity (Q) | 56.39M | |||
| Cash Flow | DTIL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -215.00K | |||
| Cash from Financing (TTM) | 50.45M | |||
| Net Change in Cash (TTM) | -8.21M | |||
| Levered Free Cash Flow (TTM) | -2.34M | |||
| Cash from Operations (TTM) | -58.45M | |||
